An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients
with relapsed or refractory lymphoma who have exhausted approved therapy options. This study
consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).